Patent: 7,553,675

Summary for Patent: 7,553,675

Title:	Diagnostic assay device having an apparent non-signal line
Abstract:	A test device and method for determining the presence or absence of one or more analytes in a fluid sample, the test device including a support or member bearing a mark thereon, and a matrix or member containing a capture zone. In operation, an observation area in the test device becomes transparent, thereby allowing the user to view a mark that is present on a support that is disposed beneath the observation area. Typically, the mark on the underlying support is configured as a minus (-) sign. In the absence of analyte in the sample, the test device presents a negative result as a minus (-) signal. In the presence of analyte in the sample, however, the mark operates in concert with a perpendicular test line on the observation area to present a positive result as a plus (+) signal that is visible to the user.
Inventor(s):	Jerome; Jeremy (Carlsbad, CA), Daquipa; Mark (San Diego, CA), Jacono; Bruce (Ramona, CA), Boehringer; Hans (San Diego, CA), Lambotte; Paul (San Diego, CA), Lawrence; Paul J. (Pacific Grove, CA)
Assignee:	Quidel Corporation (San Diego, CA)
Application Number:	11/622,201
Patent Claims:	see list of patent claims

United States Patent 7,553,675: What Do the Claims Really Cover in U.S. Point-of-Care Diagnostics?

What is US 7,553,675 claiming in plain technical terms?

US 7,553,675 claims a test strip and assay method built around a two-stage visual readout that depends on (i) a moisture-state-visible “mark” and (ii) an analyte-dependent signal from a capture zone bound by an immobilized capture reagent. The device uses one or more matrices (test strip components) positioned in fluid-flow contact so that sample fluid moves from a sample receiving zone through a label zone to an observation/capture zone.

The core claim scope (claim 1) combines these elements:

• Test strip physical structure
  • A support with a mark thereon.
  • One or more matrices in fluid-flow contact positioned over the support.
• Zone architecture
  • Sample receiving zone for applying fluid sample.
  • Label zone with a detectable mobile labeled reagent that binds analyte.
  • Observation area including a capture zone with an immobilized capture reagent.
• Detection mechanism
  • The labeled reagent produces a detectable signal in the capture zone when analyte is present.
• Moisture-state optical behavior
  • The observation area material is opaque when dry and transparent when moist.
  • The mark is detectable within the observation area when moist (so the mark becomes visible only after liquid wets the window).
• Assay interpretation
  • Claim set 4–5 introduces two-symbol logic:
  • First symbol: derived from the moisture-revealed mark.
  • Second symbol: derived from the analyte-dependent capture zone signal.
  • Combined detection indicates positive; absence of analyte indicates negative through the first symbol indicating an expected negative-state signpost while the analyte symbol does not appear.

Claims 2–3 broaden the claim by allowing the zones to be in separate matrices rather than a single monolithic matrix. Claims 6–8 add control area structure. Claims 9–10 narrow to specific materials and construction (nitrocellulose observation area; lamination on plastic backing). Claims 11–12 and 14–17 provide explicit binding targets and examples, including pregnancy (hCG) and specific antigens.

What are the key claim constraints that define the patent’s boundary?

For a U.S. infringement or validity assessment, the “hard boundaries” are those technical limitations that are nonstandard in combination:

1. Moisture-state optical switching in the observation area

   • The observation area includes a material that is opaque in a dry state and transparent in a moist state.
   • This is tied to the visibility of the support mark, which becomes detectable only after wetting.

2. Two separate detectable readouts that are “separately detectable”

   • Claim 13 requires that the mark and restrained labeled analyte are separately detectable.
   • Claims 4–5 extend this into an explicit two-symbol interpretation scheme.

3. Zone-in-fluid-flow-contact arrangement

   • Sample receiving, label, and observation/capture zones are arranged so fluid flow carries labeled reagent and allows capture at the observation area.

4. Spatially distinct control regions

   • Claims 6–8 add a control area spatially distinct from the capture zone and a control line that is spatially distinct in the matrix, with defined control area types.

5. Material specificity (optional narrowing)

   • Claims 9–10 (nitrocellulose; plastic backing lamination) and claims 11–12, 14 are narrower dependent examples.

These constraints matter because many lateral flow patents share the idea of a test line and control line. The distinctive claim differentiator here is the moisture-triggered visibility of a physical mark that lies on the underlying support, seen only through an optical window that switches from opaque to transparent.

---

How strong are the claims for enforcement? (Infringement leverage vs design-around)

Where infringement leverage is highest

Enforcement leverage is highest when an accused device:

• uses an under-support mark that becomes visible only after the strip is wetted; and
• uses an observation window material that is opaque when dry and transparent when moist; and
• requires a separate capture-zone analyte signal (typical immunochromatography) read alongside the moisture-revealed symbol.

The more an accused product uses the same “moisture reveal” architecture, the more directly it fits claim 1 and claim 13.

Claims 4–5 also increase leverage if the accused device uses two distinct symbols: one that appears based on wetting and one based on analyte binding.

Where design-around risk is highest

A competitor can reduce risk by avoiding one of the distinctive limitations:

• Replace the opaque-to-transparent observation window with a window that is always transparent, always opaque, or that uses a different activation mechanism (e.g., printed graphics that darken chemically, thermal activation, or photoreactive inks).
• Remove the mark on the support that becomes visible only after wetting.
• Use a single readout graphic where the wetting-based symbol and analyte capture symbol are not separately detectable.
• Change the control architecture so it is not spatially distinct as claimed.

Because claim 1 is structurally anchored to the moisture optical behavior and the mark visibility, those are the most likely infringement weak points under typical noninfringement analyses.

Dependent claims: leverage vs narrowing

• Claims 2–3 mainly address whether zones are separate matrices versus a single matrix; these are relatively easy to engineer around by consolidating or splitting matrices depending on readout design.
• Claims 6–8 about control areas provide narrower capture depending on the accused control-line layout.
• Claims 9–10 and 11–12 and 14–17 reduce scope by requiring specific materials or analytes. They help the patentee in markets matching those examples, but they are not needed to assert claim 1 (unless the asserted party’s device closely tracks those specifics).

---

What does the claim set imply about the commercial intent?

The architecture targets a common operational problem in point-of-care strips: users need a reliable readout that distinguishes test validity/wetting status from analyte presence.

Claim language that supports that intent:

• The moisture-dependent visibility of the mark provides a built-in wetting/handling cue.
• The analyte capture zone provides the binding-based positive/negative signal.
• The two-symbol scheme provides a more robust interpretation than relying on a single line.

From a competitive view, products that aim to improve user confidence or reduce invalid reads are most likely to converge on similar design features.

---

Patent landscape: what is likely to exist around these ideas

What categories of prior art tend to intersect with this claim set

Even without enumerating every patent number in the public record here, the claim features map to three common technological “prior art neighborhoods”:

1. Lateral flow immunoassays (LFIA) with labeled reagents and capture zones

   • Broad prior art exists for sample receiving zones, label zones with mobile labeled binding reagents, and capture zones with immobilized capture reagents.

2. Control line / validity features

   • Control areas and spatially distinct control lines are standard across pregnancy tests, infectious disease tests, and rapid diagnostics.

3. Visually readable “read” windows and moisture/wetting dependent visual confirmation

   • Some prior art uses color development tied to fluid flow, but claim 1’s specific optical property (opaque when dry, transparent when moist) tied to a mark on the support is narrower.

The combination of (i) an LFIA architecture plus (ii) moisture-state optical switching to reveal a hidden mark plus (iii) separately detectable mark vs analyte capture is the likely novelty locus that critics will focus on for obviousness.

---

Critical analysis of novelty and obviousness risk

Potential novelty strength

The most likely novelty argument is that many LFIA systems have control lines, but fewer combine:

• an under-support mark;
• a window material that changes optical transmission upon wetting (opaque dry, transparent moist); and
• a requirement that the mark is detectable within the observation area only when moist, while the analyte capture signal is separately detectable.

If the prior art shows only a single color change or only a wetting-based color development on the detection matrix, that may not anticipate the claim’s optical switching structure.

Potential obviousness weakness

A common attack is that:

• selecting a transmissive/opaque polymer or coating that becomes transparent upon hydration is a routine engineering decision;
• hiding a printed symbol under a window and revealing it upon wetting is a known human-factors approach; and
• integrating that with an otherwise conventional LFIA structure could be argued as an obvious combination.

The dependent control-line and two-symbol logic can also be attacked as an obvious extension of existing test interpretation conventions.

How claims 4–5 could affect obviousness

The two-symbol logic is a further narrowing, but it also can be argued as routine:

• “First symbol appears due to wetting status” plus
• “Second symbol appears due to analyte binding” is a predictable mapping in diagnostics.

If prior art discloses separate validity and test-result signals, the only remaining differentiator is whether the validity signal comes from a moisture-revealed support mark through an opaque-to-transparent observation window.

Material-specific dependencies: do they rescue validity?

Claims 9–10 (nitrocellulose observation area; laminated plastic backing) likely do not rescue validity if the novelty is in optical switching and mark visibility, because nitrocellulose and backing laminations are common.

Claims 11–12 and 14–17 depend on binding targets and analytes; they are unlikely to rescue validity from a structural obviousness challenge unless the accused combination is tied to those exact analytes and targets in the prior art.

---

Claim-by-claim landscape implications

Claim 1 (independent): strongest boundary

Any competitive product that lacks the opaque-to-transparent moisture switching in the observation area or lacks a support mark becoming detectable in the moist state is likely outside literal scope.

Claims 2–3: matrix separation

If competitor consolidates sample receiving, label, and observation into a single matrix, they may still infringe claim 1, because claim 1 already uses one or more matrices. These dependent claims add fallback positions rather than independent drivers.

Claims 4–5: two-symbol read logic

If the mark and analyte signals are presented in distinct visual regions, these claims may capture systems that already have a test-and-control architecture, but only if the “first symbol” meets the moisture-dependent mark detectability limitation.

Claims 6–8: defined control region

These add conventional control topology. They can matter if the accused device uses a single control line and does not create a spatially distinct control area in the claimed manner.

Claims 9–10: nitrocellulose and lamination

These are narrower fallback. Many devices use nitrocellulose in lateral flow immunoassays, but the “observation area” may be made from other membranes or composite windows. If so, claim 9 may be less relevant.

Claims 11–12 and 14–17: analyte examples

These anchor commercial applicability to specific markets (pregnancy hCG, and specific antigens). They help enforcement where an accused device matches those analytes.

---

Business-critical takeaways for asserting or designing around

If you are asserting US 7,553,675

Your strongest factual roadmap is to prove that the accused device includes:

• a defined observation area whose optical property changes from opaque (dry) to transparent (wet); and
• a mark on the support that becomes visible only when wet; and
• separate detectability of wetting-based mark and analyte-capture restrained labeled reagent signal.

These map directly to claim 1 and claim 13.

If you are designing a competing strip

Your strongest design-around is to eliminate at least one of:

• moisture-state optical switching of the observation material (opaque dry, transparent moist); or
• the support mark visibility concept; or
• separate detectability requirement by merging visual logic into a single integrated signal.

---

Key Takeaways

• US 7,553,675 centers on moisture-triggered visibility: the observation area is opaque when dry and transparent when moist, revealing a mark on the support in the wet state.
• Claim 1 then overlays conventional analyte binding readout: a mobile labeled reagent binds analyte and produces a capture-zone signal in the observation area.
• Enforcement turns on the moisture-optical window and mark architecture: without those, typical lateral flow test-and-control designs are unlikely to map onto claim 1.
• Dependent claims add practical fallback positions: separation of matrices, two-symbol logic, and spatially distinct control areas tighten interpretation but do not replace the core optical switching limitation.
• Design-around is feasible by changing the visibility mechanism: avoiding opaque-to-transparent wetting windows or eliminating the under-support mark likely reduces literal infringement risk.

---

FAQs

1) Does US 7,553,675 cover standard pregnancy cassette tests with only a test line and control line?

Not on the face of claim 1. Standard test-and-control systems lack the moisture-state opaque-to-transparent observation area that reveals a support mark when wet.

2) What is the most important limitation to check first in an accused product?

Whether the observation area material is opaque in a dry state and transparent in a moist state, and whether a mark on the support becomes detectable in that moist state.

3) Are the nitrocellulose and lamination limitations required to reach claim coverage?

No. Nitrocellulose and plastic backing lamination are in dependent claims (9 and 10). Claim 1 does not require those specific materials.

4) Can competitors avoid infringement by changing analytes?

Changing analyte targets affects dependent claims (11–12, 14–17) but does not avoid claim 1 if the structural and readout architecture remains the same.

5) How does the “two symbols” logic change the infringement assessment?

It strengthens coverage where the device displays a moisture revealed first symbol and an analyte-dependent second symbol that together indicate positive or negative results.

---

References

[1] United States Patent 7,553,675, “Test device for determining the presence or absence of an analyte in a fluid sample,” claims 1–17 (provided).

Details for Patent 7,553,675

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2027-01-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2027-01-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2027-01-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2027-01-11
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2027-01-11